Please login to read the full article.
Scrip Regulatory Affairs
EMA reflection paper on generic nanoparticle iron products: a case of bias by omission?
21 July 2011
David Snodin
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications
- EU scientific panel to undertake risk assessment of medical devices containing nanomaterials
- New Swiss requirements on submissions for generics and products with known APIs get industry thumbs up
- Prometheus dissected: Will chaos rule in US patenting?
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
EDITORIALS
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Other Informa Comments
